Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Associatio...

Full description

Bibliographic Details
Main Authors: Graziella Bruno, Bartolomeo Lorenzati, Chiara Zucco, Sara Miglietta, Federico Lamberti
Format: Article
Language:English
Published: MDPI AG 2010-09-01
Series:Pharmaceuticals
Subjects:
hypoglycemic drugs
sulfonylureas
thiazolidinediones
incretin mimeticshypoglycemic drugs
incretin mimetics
Online Access:http://www.mdpi.com/1424-8247/3/9/3005/

Similar Items

Similar Items